# Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

> **NCT04854928** · PHASE2 · UNKNOWN · sponsor: **Pharma Holdings AS** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** LTX-109 gel, 3%
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT04854928
- **Lead sponsor:** Pharma Holdings AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-03
- **Primary completion:** 2022-02
- **Final completion:** 2022-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854928, "Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04854928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*